Early Signs of Altitude Illness in Patients With COPD

University of Zurich153 enrolled

Overview

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel. After baseline evaluation at 760 m, patients will travel by bus within 3-5 h to the Tuja Ashu high altitude clinic at 3'100 m and stay there for 2 days. During this period, participants will perform SSM. They are instructed to report to study personnel if they fulfill predefined criteria for impeding altitude-related illness. A planned interim analysis will be performed after the first year of the study or after completion of study by 80 participants, whichever comes first to allow any necessary adaptations of the sample size or terminate the study early for futility or high accuracy of the index test.

Study Type

OBSERVATIONAL

Enrollment

153

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Structured self-monitoring during an altitude ascent and stay at high altitudeDIAGNOSTIC_TEST

Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion criteria * Male and female patients, age 18-75 yrs. * COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92%, PaCO2 \<6 kPa at 760 m. * Born, raised and currently living at low altitude (\<800 m). * Written informed consent. Exclusion criteria * COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1 \<40% predicted; oxygen saturation on room air \<92% or hypercapnia at 760 m). * Other lung disease or disorder of control of breathing * Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke, internal, neurologic, rheumatologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day)

Locations (1)

National Center of Cardiology and Internal Medicine

Bishkek, Kyrgyzstan

Outcomes

Primary Outcomes

Diagnostic accurarcy measures of structured self-monitoring

Diagnostic performance includes sensitivity, specificity, positive and negative predictive values, and receiver operator curve area under the the curve. The diagnostic performance will be compared statistically using c-statistics against the reference test. Reference test will be the occurence of altitude-related illness defined as the following: * AMS defined by the Lake Louise questionnaire score or with AMSc score * severe hypoxemia (SpO2 \<80% at rest \>30 min; or SpO2 \<75% at rest \>15 min; * intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators. * dyspnea or discomfort at rest requiring treatment with oxygen * chest pain or ECG signs of cardiac ischemia * severe hypertension: systolic blood pressure \>200 mmHg, diastolic blood pressure \>110 mmHg * new onset neurologic impairment * Any condition that requires study withdrawal according to the decision of the independent physician

Time frame: Day 1 to 3 at 3100m

Secondary Outcomes

Acute mountain sickness severity assessed by the Lake Louise score

The severity of acute mountain sickness will be assessed by the Lake Louise questionnaire. The severity will be calculated when the presence of headache and at least one of the following symptoms is present: gastrointestinal upset, fatigue or weakness and dizziness or lightheadedness. Each of the four questions is asked with the corresponding 0 to 3 rating of the response (0 = Not present, 1 = mild, 2 = moderate, 3 = severe). The sum of the responses on these questions is then calculated, resulting in the AMS severity.

Time frame: Day 1 to 3 at 3100m

Altitude-related illness, incidence

Incidence of ARI during the stay at 3100 m. ARI is defined as the following: * AMS defined by the Lake Louise questionnaire score or with AMSc score * severe hypoxemia (SpO2 \<80% at rest \>30 min; or SpO2 \<75% at rest \>15 min; * intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators. * dyspnea or discomfort at rest requiring treatment with oxygen * chest pain or ECG signs of cardiac ischemia * severe hypertension: systolic blood pressure \>200 mmHg, diastolic blood pressure \>110 mmHg * new onset neurologic impairment * Any condition that requires study withdrawal according to the decision of the independent physician

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.